On February 11, 2026, Nektar Therapeutics reported an underwriting agreement for an offering of approximately 6.6 million shares of common stock at $58.00 each, expected to raise about $432 million after expenses. The sale includes additional options for underwriters to purchase more shares and the offering is set to close on February 13, 2026.